ID   Mac-1
AC   CVCL_H631
SY   MAC-1; MAC1; McG-1
DR   BTO; BTO:0004869
DR   cancercelllines; CVCL_H631
DR   Cell_Model_Passport; SIDM01369
DR   Cosmic; 2013355
DR   Cosmic; 2674499
DR   Cosmic; 2814456
DR   GEO; GSM1217151
DR   GEO; GSM2527945
DR   Progenetix; CVCL_H631
DR   Wikidata; Q54903946
RX   CelloPub=CLPUB00077;
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=1532439;
RX   PubMed=2456698;
RX   PubMed=2898211;
RX   PubMed=9162223;
RX   PubMed=28356514;
RX   PubMed=29533902;
CC   Omics: Transcriptome analysis by RNAseq.
CC   Donor information: Originally the patient was suffering from Hodgkin lymphoma.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
CC   Cell type: T-cell; CL=CL_0000084.
DI   NCIt; C3467; Primary cutaneous T-cell non-Hodgkin lymphoma
DI   ORDO; Orphanet_171901; Primary cutaneous T-cell lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_H632 ! Mac-2
SX   Male
AG   45Y
CA   Cancer cell line
DT   Created: 11-02-13; Last updated: 05-10-23; Version: 17
//
RX   CelloPub=CLPUB00077;
RA   Kadin M.E., Sako D., Morton C., Newcom S.R., Su I.-J.;
RT   "Characterization of a neoplastic T cell line from a patient with
RT   cutaneous T cell lymphoma and regressing T cell skin lesions.";
RL   Lab. Invest. 58:45A-45A(1988).
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=1532439; DOI=10.1056/NEJM199204233261704;
RA   Davis T.H., Morton C.C., Miller-Cassman R., Balk S.P., Kadin M.E.;
RT   "Hodgkin's disease, lymphomatoid papulosis, and cutaneous T-cell
RT   lymphoma derived from a common T-cell clone.";
RL   N. Engl. J. Med. 326:1115-1122(1992).
//
RX   PubMed=2456698;
RA   Su I.-J., Balk S.P., Kadin M.E.;
RT   "Molecular basis for the aberrant expression of T cell antigens in
RT   postthymic T cell malignancies.";
RL   Am. J. Pathol. 132:192-198(1988).
//
RX   PubMed=2898211;
RA   Newcom S.R., Kadin M.E., Ansari A.A.;
RT   "Production of transforming growth factor-beta activity by Ki-1
RT   positive lymphoma cells and analysis of its role in the regulation of
RT   Ki-1 positive lymphoma growth.";
RL   Am. J. Pathol. 131:569-577(1988).
//
RX   PubMed=9162223; DOI=10.1006/cyto.1996.0044;
RA   Marti R.M., Wasik M.A., Kadin M.E.;
RT   "Constitutive secretion of GM-CSF by three different cell lines
RT   derived from a single patient with a progressive cutaneous
RT   lymphoproliferative disorder.";
RL   Cytokine 8:323-329(1996).
//
RX   PubMed=28356514; DOI=10.1073/pnas.1700682114;
RA   Chen J., Zhang Y., Petrus M.N., Xiao W.-M., Nicolae A., Raffeld M.,
RA   Pittaluga S., Bamford R.N., Nakagawa M., Ouyang S.T.-Y., Epstein A.L.,
RA   Kadin M.E., Del Mistro A., Woessner R.D., Jaffe E.S., Waldmann T.A.;
RT   "Cytokine receptor signaling is required for the survival of ALK-
RT   anaplastic large cell lymphoma, even in the presence of JAK1/STAT3
RT   mutations.";
RL   Proc. Natl. Acad. Sci. U.S.A. 114:3975-3980(2017).
//
RX   PubMed=29533902; DOI=10.1515/hsz-2017-0321;
RA   Drexler H.G., Pommerenke C., Eberth S., Nagel S.;
RT   "Hodgkin lymphoma cell lines: to separate the wheat from the chaff.";
RL   Biol. Chem. 399:511-523(2018).
//